...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Prognostic Significance of Serum Tumor Markers in Patients with Advanced-stage NSCLC Treated with Pemetrexed-based Chemotherapy
【24h】

Prognostic Significance of Serum Tumor Markers in Patients with Advanced-stage NSCLC Treated with Pemetrexed-based Chemotherapy

机译：培美曲塞为基础的化学疗法治疗晚期NSCLC患者血清肿瘤标志物的预后意义

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Tumor biomarkers represent effective tools for diagnostics and follow-up monitoring of patients with non-small cell lung cancer (NSCLC). We focused on evaluating the predictive and prognostic role of the seven following tumor biomarkers: carcinoembryonic antigen (CEA), cytokeratin-19 fragment (CYFRA 21-1), fragments of cytokeratin 8, 18 and 19 (MonoTotal), neuron-specific enolase (NSE), chromogranin A, thymidine kinase (TK) and squamous cell carcinoma antigen (SCCA) in patients with advanced-stage NSCLC treated with pemetrexed-based chemotherapy. Patients and Methods: In total, 114 patients with advanced-stage (IIIB or IV) non-squamous NSCLC treated with pemetrexed-based chemotherapy (monotherapy or combination with a platinum derivative) were included. Comparison of progression-free (PFS) and overall survival (OS) according to the level of assessed tumor markers was performed using the log-rank test. Results: We recorded significantly shorter OS for patients with high pretreatment levels of CYFRA 21-1 (10.3 vs. 23.4 months; p<0.001), NSE (1.6 vs. 13.5 months; p=0.003) and TK (11.3 vs. 23.4 months; p=0.003). Conclusion: CYFRA 21-1, NSE and TK are feasible biomarkers for estimation of a patient's overall prognosis, however, none of the measured serum tumor markers were able to predict the efficacy of pemetrexed-based chemotherapy.
机译：背景：肿瘤生物标志物是诊断和跟踪监测非小细胞肺癌（NSCLC）患者的有效工具。我们专注于评估以下七个肿瘤生物标志物的预测和预后作用：癌胚抗原（CEA），细胞角蛋白19片段（CYFRA 21-1），细胞角蛋白8、18和19（MonoTotal）片段，神经元特异性烯醇化酶（ NSE），嗜铬粒蛋白A，胸苷激酶（TK）和鳞状细胞癌抗原（SCCA）用于以培美曲塞为基础的化疗治疗的晚期NSCLC患者。患者和方法：总共纳入114例以培美曲塞为基础的化疗（单一疗法或联合铂衍生物）治疗的晚期（IIIB或IV）非鳞状非小细胞肺癌患者。使用对数秩检验，根据评估的肿瘤标志物水平比较无进展（PFS）和总生存期（OS）。结果：我们记录了CYFRA 21-1（10.3 vs. 23.4个月; p <0.001），NSE（1.6 vs. 13.5个月; p = 0.003）和TK（11.3 vs. 23.4个月）的高预处理水平的患者的OS明显缩短。 ; p = 0.003）。结论：CYFRA 21-1，NSE和TK是评估患者总体预后的可行生物标志物，但是，所测血清肿瘤标志物均不能预测以培美曲塞为基础的化疗的疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号